All In Biotech

Drug Trial Radar · NCT03852823

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours

An Open, Multi-dose, Dose Escalation and Cohort Expansion, Phase Ⅰ Study of the Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours.

Last checked: Nov 19, 2026Latest source record: Apr 30, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

192

Planned (sponsor's estimate)

Start

May 23, 2019

Primary completion

Sep 2022

Study completion Mar 2023

Sponsor

Sponsor type
Industry
First posted
Feb 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open, multi-dose, dose escalation and cohort expansion, phase Ⅰ study to investigate the safety, tolerability, efficiency, pharmacokinetics, immunogenicity of SG001 in subjects with advanced tumours.

Conditions

  • Advanced Solid Tumours
  • Cervical Cancer
  • Malignant Mesothelioma
  • Lymphoma
  • Non-Small-Cell Lung Cancer

Interventions

  • SG001Drug

    Phase Ia: Subjects will receive intravenous infusion of SG001 following a sequential dose escalation design (1mg/kg, 3mg/kg and 10mg/kg). Dose limited toxicity (DLT) will be observed within 21 days after the first administration, then subjects can continuously receive SG001 every 2 weeks until confirmed progression, unacceptable toxicity, or withdrawal from the trial. Phase Ib: Subjects will receive intravenous infusion of SG001 at the dose of 240 mg every 2 weeks until confirmed progression, unacceptable toxicity, or withdrawal from the trial.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of SG001 by assessing the percentage of participants who experience a dose-limiting toxicity (DLT)Time frame: Phase Ⅰa: 21 days
  2. Objective response rate (ORR) in solid tumor(The ORR of cohort B, C, and E will be evaluated by Independent Review Committee).Time frame: Phase Ⅰb: From date of first drug administration until the date of first documented progression of disease or the date of death or the date of lose to follow-up, which occurs first, assessed up to 2 years.
  3. Safety of SG001 in patients with advanced tumors.Time frame: Phase Ⅰb: From signing informed consent form (ICF) to 90 days after the last dose of study drug or initiation of a new therapy for cancer, which occurs first.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.